Geriatric Psychiatry Division, Centre for Addiction and Mental Health/University of Toronto, Toronto, ON, Canada.
Geriatric Psychiatry Division, Vancouver Island Health Authority, Victoria, BC, Canada.
J Psychopharmacol. 2022 Sep;36(9):1007-1015. doi: 10.1177/02698811221115758. Epub 2022 Aug 31.
Drugs used to treat psychotic disorders ('antipsychotics') have been widely used in psychiatry since the introduction of chlorpromazine in the mid-1950s. The categorization of these drugs evolved in a piecemeal way, relying initially on grouping by chemical structure (e.g. phenothiazines, butyrophenones), then by epoch of introduction (e.g. first generation ('conventional') vs second generation ('atypical')). As psychopharmacological expertise has advanced, it has become possible to quantify affinities for each drug in this class for relevant receptors including dopamine D2, 5HT2A, 5HT2C, histamine H1 and others. However, until the recent emergence of a new generation of agents known collectively as dopamine D2 receptor partial agonists (e.g. aripiprazole, brexpiprazole and cariprazine), there had been little reference in drug classification to specific pharmacological properties. An overview of data on receptor affinities across multiple drugs and receptor types would permit categorization according to binding affinities and putative pharmacological mechanisms. In this paper, we have attempted to construct a 'subway map' of 32 drugs used for treatment of psychotic disorders. This design allows a visualization of both the historical classifications by structure and epoch of introduction, and of the binding affinities for key receptors based on appraisal of scientific literature. The map represents a step towards categorization by mechanism, allowing prescribers and patients to understand which drugs share common biological features and the extent to which drugs may have similarities and differences in their mechanisms. In addition, this approach may encourage more logical groupings of drugs to be used in systematic reviews and meta-analyses.
自 20 世纪 50 年代氯丙嗪问世以来,用于治疗精神障碍(“抗精神病药”)的药物在精神病学中得到了广泛应用。这些药物的分类是逐步发展的,最初是根据化学结构进行分组(例如:吩噻嗪类、丁酰苯类),然后根据引入的时间进行分组(例如:第一代(“传统”)与第二代(“非典型”))。随着精神药理学专业知识的进步,已经可以量化该类药物与相关受体(包括多巴胺 D2、5HT2A、5HT2C、组胺 H1 等)的亲和力。然而,直到最近新一代被统称为多巴胺 D2 受体部分激动剂的药物(例如:阿立哌唑、布瑞哌唑和卡利拉嗪)出现之前,药物分类中很少提及特定的药理学特性。对多种药物和受体类型的受体亲和力数据进行概述,可以根据结合亲和力和潜在的药理学机制进行分类。在本文中,我们试图构建一个用于治疗精神障碍的 32 种药物的“地铁图”。这种设计允许同时可视化结构和引入时间的历史分类,以及基于评估科学文献的关键受体的结合亲和力。该地图代表了迈向机制分类的一步,使处方者和患者能够了解哪些药物具有共同的生物学特征,以及药物在其机制中可能具有相似性和差异性的程度。此外,这种方法可能会鼓励更合理地将药物分组用于系统评价和荟萃分析。